Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Benzene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL1837317 | 0.90 | TSHR (0.61) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Sulfuric Acid SCHEMBL700465 | 0.90 | — | — | |
| Sulfuric Acid SCHEMBL18321864 | 0.87 | TSHR (0.57) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Sulfuric Acid SCHEMBL28788758 | 0.87 | TSHR (0.57) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Sulfuric Acid SCHEMBL27805126 | 0.87 | TSHR (0.57) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Sulfuric Acid SCHEMBL27766607 | 0.84 | TSHR (0.53) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Benzene SCHEMBL1227479 | 0.83 | TSHR (0.73) | TSHRALDH1A1BLMLMNASMN1; SMN2 | |
| Sulfuric Acid SCHEMBL11574267 | 0.81 | TSHR (0.50) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Sulfuric Acid SCHEMBL28363659 | 0.81 | TSHR (0.50) | TSHRALDH1A1BLMLMNASLC6A6 | |
| Sulfamate SCHEMBL2367969 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017358-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2004-08-11 | — | — | EP | claimed |
| EP-1017358-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-07-12 | — | — | EP | claimed |
| US-5939458-A | APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN | GILLETTE COMPANY, THE | 1999-08-17 | — | — | US | claimed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| EP-3212183-B1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | UNIV ROCHESTER (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10028931-B2 | Synergistic compositions for treating microbial infections | UNIVERSITY OF ROCHESTER (US) | 2018-07-24 | — | — | US | disclosed |
| EP-3212183-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | University of Rochester (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170246139-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | UNIVERSITY OF ROCHESTER (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2016070021-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | UNIVERSITY OF ROCHESTER (US) | 2016-05-06 | — | — | WO | disclosed |
| US-8778631-B2 | Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system | SUTRO BIOPHARMA, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2376647-B1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2379578-A1 | DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD | Sutro Biopharma, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100184134-A1 | DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD | SUTRO BIOPHARMA, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184135-A1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010081111-A1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081110-A1 | DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD | SUTRO BIOPHARMA, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1017358-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1017358-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5939458-A | APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN | GILLETTE COMPANY, THE | 1999-08-17 | — | — | US | disclosed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028931-B2 | Synergistic compositions for treating microbial infections | RNASE1, RNASEL, RNASEH1 | TSHR 3242/4885ALDH1A1 3822/4885BLM 1158/4885 |
| US-20170246139-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | RNASE1, RNASEL, RNASEH1 | TSHR 3242/4885ALDH1A1 3822/4885BLM 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.